76 related articles for article (PubMed ID: 23016583)
1. Synergistic enhancement of cancer therapy using a combination of fusion protein MG7-scFv/SEB and tumor necrosis factor alpha.
Lu X; Cheng C; Wang G; Shu X; Ma J; Tong Q
Protein Pept Lett; 2013 Apr; 20(4):467-72. PubMed ID: 23016583
[TBL] [Abstract][Full Text] [Related]
2. Construction and characterization of a novel fusion protein MG7-scFv/SEB against gastric cancer.
Tong Q; Liu K; Lu XM; Shu XG; Wang GB
J Biomed Biotechnol; 2010; 2010():121094. PubMed ID: 20339532
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
[TBL] [Abstract][Full Text] [Related]
4. [Production of phage-displayed anti-idiotypic antibody single chain variable fragments to MG7 monoclonal antibody directed against gastric carcinoma].
He F; Nie Y; Han Z
Zhonghua Yi Xue Za Zhi; 2001 Jan; 81(1):33-6. PubMed ID: 11798849
[TBL] [Abstract][Full Text] [Related]
5. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
6. A trimeric anti-HER2/neu ScFv and tumor necrosis factor-alpha fusion protein induces HER2/neu signaling and facilitates repair of injured epithelia.
Huang TH; Morrison SL
J Pharmacol Exp Ther; 2006 Mar; 316(3):983-91. PubMed ID: 16291729
[TBL] [Abstract][Full Text] [Related]
7. Preparation and In Vitro Evaluation of Antitumor Activity of TGFαL3-SEB as a Ligand-Targeted Superantigen.
Yousefi F; Mousavi SF; Siadat SD; Aslani MM; Amani J; Rad HS; Fooladi AA
Technol Cancer Res Treat; 2016 Apr; 15(2):215-26. PubMed ID: 25759426
[TBL] [Abstract][Full Text] [Related]
8. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
Crippa L; Gasparri A; Sacchi A; Ferrero E; Curnis F; Corti A
Cancer Res; 2008 Feb; 68(4):1154-61. PubMed ID: 18281491
[TBL] [Abstract][Full Text] [Related]
9. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
10. Tagging staphylococcal enterotoxin B (SEB) with TGFaL3 for breast cancer therapy.
Yousefi F; Siadat SD; Saraji AA; Hesaraki S; Aslani MM; Mousavi SF; Imani Fooladi AA
Tumour Biol; 2016 Apr; 37(4):5305-16. PubMed ID: 26561468
[TBL] [Abstract][Full Text] [Related]
11. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.
Bremer E; Samplonius DF; Peipp M; van Genne L; Kroesen BJ; Fey GH; Gramatzki M; de Leij LF; Helfrich W
Cancer Res; 2005 Apr; 65(8):3380-8. PubMed ID: 15833872
[TBL] [Abstract][Full Text] [Related]
12. Construction and characterization of a novel superantigen fusion protein: bFGF/SEB.
Wang L; Zhang H; Zhang S; Yu M; Yang X
Cancer Invest; 2009 May; 27(4):376-83. PubMed ID: 19160106
[TBL] [Abstract][Full Text] [Related]
13. Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines.
Kim DM; Koo SY; Jeon K; Kim MH; Lee J; Hong CY; Jeong S
Cancer Res; 2003 Feb; 63(3):621-6. PubMed ID: 12566305
[TBL] [Abstract][Full Text] [Related]
14. [Anti-tumor effect of lentivirus-mediated MUCI antibody-targeted gene therapy with VP22-TK system on MUC1(+) human ovarian cancer transplanted intraperitoneally in nude mice].
Kong B; Wang W; Liu C; Ma D; Qu X; Jiang J; Yang X; Zhang Y; Jiang S
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(17):1207-10. PubMed ID: 12475412
[TBL] [Abstract][Full Text] [Related]
15. Effect of low-dose tumor necrosis factor-alpha in combination with STEALTH liposomal cisplatin (SPI-077) on soft-tissue- and osteosarcoma-bearing rats.
Hoving S; van Tiel ST; Eggermont AM; ten Hagen TL
Anticancer Res; 2005; 25(2A):743-50. PubMed ID: 15868905
[TBL] [Abstract][Full Text] [Related]
16. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
[TBL] [Abstract][Full Text] [Related]
17. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
18. TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor.
Wüest T; Gerlach E; Banerjee D; Gerspach J; Moosmayer D; Pfizenmaier K
Oncogene; 2002 Jun; 21(27):4257-65. PubMed ID: 12082613
[TBL] [Abstract][Full Text] [Related]
19. One-step on-column purification and refolding of a single-chain variable fragment (scFv) antibody against tumour necrosis factor alpha.
Liu M; Wang X; Yin C; Zhang Z; Lin Q; Zhen Y; Huang H
Biotechnol Appl Biochem; 2006 Mar; 43(Pt 3):137-45. PubMed ID: 16293104
[TBL] [Abstract][Full Text] [Related]
20. Expression and bioactivity identification of soluble MG7 scFv.
Yu ZC; Ding J; Pan BR; Fan DM; Zhang XY
World J Gastroenterol; 2002 Feb; 8(1):99-102. PubMed ID: 11833081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
